Acquisition - March 12, 2015
AstraZeneca Buys More Respiratory Business
AstraZeneca recently acquired the rights to Actavis’ branded respiratory business in the US and Canada, according to a company announcement. As part of the agreement, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Actavis an additional $100 million for […]
Acquisition - February 18, 2015
AstraZeneca to Acquire Actavis’ Branded Respiratory Side in U.S., Canada
AstraZeneca plans to acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. When the transaction is finalized, AstraZeneca will own the development and commercial rights in the US and Canada to TudorzaTM PressairTM […]
